
Toni Choueiri, MD
@drchoueiri
Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow @GMA
ID: 4827883464
https://www.dana-farber.org/find-a-doctor/toni-choueiri/ 29-01-2016 00:40:02
26,26K Tweet
38,38K Followers
477 Following

Outstanding talk from silke gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra223 to enzalutamide as first-line therapy for mCRPC showed significant rPFS improvement + significant OS benefit #ESMO24 ESMO - Eur. Oncology OncoAlert UroToday.com
